Synergistic seizure reduction in patient with persistently elevated N-desmethylclobazam levels, CYP450 genetic polymorphism, and responsive neurostimulator targeting centromedian nuclei of bilateral thalami

Synergistic seizure reduction in patient with persistently elevated N-desmethylclobazam levels, CYP450 genetic polymorphism, and responsive neurostimulator targeting centromedian nuclei of bilateral thalami

Clobazam (CLB) and cenobamate (CNB) are commonly used antiseizure medications (ASMs) in the treatment of patients with drug-resistant epilepsy (DRE). However, concomitant use of these two ASMs may lead to significant treatment-related adverse events (TRAE). Furthermore, these TRAE may be exacerbated...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrew Zillgitt, David E Burdette, Atheel Yako, Revati Rashingkar, Ashleigh Terrell, Sydney Jacobs, Michael D Staudt
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Epilepsy & Behavior Reports
Subjects:
Clobazam
Cenobamate
Pharmacogenetics
Idiopathic generalized epilepsy
Responsive neurostimulator
Online Access:http://www.sciencedirect.com/science/article/pii/S2589986425000590
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items